Boufarik, Algeria – Saidal Group, in partnership with Novo Nordisk, officially launched its new generation insulin pens in the Algerian market today. The new product, Tresiba, is part of a strategic partnership aimed at advancing diabetes treatment and strengthening national health security.
The launch ceremony took place at Novo Nordisk’s headquarters in Boufarik, Blida province. The event was attended by Nabila Benyagzer, CEO of Saidal Group, Hamza Benharrat, General Manager of Novo Nordisk Algeria, senior executives from both companies, and representatives from national and local authorities.
According to a statement from Saidal, both parties have intensified their efforts and worked closely together to expedite this vital project, given the significant challenge that diabetes poses to public health in Algeria. Initial discussions began in September, followed by the signing of a Memorandum of Understanding and a contract in October. The product is now available in the national market.
Saidal has already initiated the full production process at its Constantine site, with the goal of localizing the manufacturing of this medication as soon as possible. The agreement also stipulates the gradual integration of innovative therapeutic solutions developed by Novo Nordisk, ensuring that Algerian patients benefit from modern and effective treatments that meet international standards.
This initiative represents a significant step forward in diabetes care and aligns with the national strategy to boost local pharmaceutical production, reduce import dependence, and bolster the country’s health security, in accordance with the directives of President Abdelmadjid Tebboune. This launch underscores Saidal’s commitment to providing cutting-edge healthcare solutions to the Algerian population.
